Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-5635 Injection in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Yi Lu
- 전화번호: 0518-82342973
- 이메일: minghao.lyu@hengrui.com
연구 장소
-
-
Guangzhou
-
Guangzhou, Guangzhou, 중국, 510515
- 모병
- Nanfang Hospital, Southern Medical University
-
수석 연구원:
- Jinlin Hou
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Chronic hepatitis B defined as HBV infection documented for at least 6 months prior to screening;
- Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation;
- HBeAg negative at screening;
- On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 4 weeks before randomization;
- Need to take effective contraceptive measures;
- Volunteer to sign an informed consent.
Exclusion Criteria:
- History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic hepatitis B that may affect the evaluation of the study;
- With autoimmune disease;
- History of solid organ transplantation or hematopoietic stem cell transplantation;
- Clinically significant and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases;
- Malignant tumors were diagnosed within 5 years prior to randomization;
- Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results;
- Laboratory tests during the screening period were obviously abnormal;
- Prolonged ECG QTcF or other clinically significant abnormal results that may pose a significant safety risk to the subject during the screening period;
- History of drug use, alcohol or drug abuse in the 12 months prior to randomization;
- Participated in clinical study of other drugs (received experimental drugs);
- Pregnant or nursing women;
- Allergic to a drug ingredient or component;
- Other reasons for ineligibility as judged by the investigators.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Placebo, administered by subcutaneous injection. |
|
실험적: HRS-5635 Injection
|
HRS-5635 Injection, administered by subcutaneous injection; |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg loss within 24 weeks after discontinuation of all HBV therapy
기간: 24 weeks after discontinuation of all CHB treatment
|
24 weeks after discontinuation of all CHB treatment
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 100 IU/mL
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 10 IU/mL
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 100 IU/mL
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 10 IU/mL
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Changes from baseline in mean log10 HBsAg levels
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg loss
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg seroconversion
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBeAb positive
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with virologic breakthrough
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with drug resistance
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Relapse rate after discontinuation of NAs therapy
기간: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Treatment-emergent adverse events
기간: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Percentage of participants with detectable anti-drug antibodies
기간: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants who meet the criteria for stopping nucleos(t)ide analogue (NA) therapy
기간: Week 72 and Week 96
|
Week 72 and Week 96
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- HRS-5635-301
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .